Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394686 | 0.89 | TACR1 (0.44) | TACR1STSJAK2JAK1PAK1 | |
| SCHEMBL5395886 | 0.89 | TACR1 (0.43) | TACR1STSJAK2JAK1PAK1 | |
| SCHEMBL5400644 | 0.88 | TACR1 (0.56) | TACR1HDAC6CYP3A4 | |
| SCHEMBL6259791 | 0.86 | CCR1 (0.39) | TACR1CCR1 | |
| SCHEMBL5389958 | 0.86 | TACR1 (0.52) | TACR1STSJAK2JAK1PAK1 | |
| SCHEMBL5390865 | 0.84 | TACR1 (0.50) | TACR1STSJAK2JAK1CNR1 | |
| SCHEMBL5388332 | 0.78 | HDAC6 (0.47) | JAK2JAK1HDAC6GPR119USP30 | |
| SCHEMBL5398236 | 0.78 | TACR1 (0.57) | TACR1CYP3A4 | |
| SCHEMBL5398539 | 0.77 | TACR1 (0.49) | TACR1PAK1GPR119CCR1 | |
| SCHEMBL5398565 | 0.77 | TACR1 (0.52) | TACR1JAK2JAK1GPR119CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214680-B2 | 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | SLC6A4, TPH1, HTR1D | TACR1 49/4885STS 1794/4885JAK2 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.